Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Clinical trials sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Triple threat: new combo aims to outsmart advanced liver cancer Results expected Sep 2026 (estimated)
- New dermatitis drug candidate begins first human safety tests Results expected Oct 2026 (estimated)
- New hope for advanced cancer: experimental drug SHR-1681 enters human trials Results expected Nov 2026 (estimated)
- New hope for EGFR lung cancer: experimental drug SHR-A2009 takes on chemo in phase 3 trial Results expected Dec 2026 (estimated)
- Can a new drug tame metastatic prostate cancer? a phase 1 trial aims to find out Results expected Dec 2026 (estimated)
-
New injectable drug tested for safety in Hard-to-Treat solid tumors
Disease control Not yet recruitingResearchers are running a phase 1 trial of SHR-4595, an experimental injectable drug, in adults with advanced solid tumors that have not responded to standard treatments. The study checks how safe and tolerable the drug is, how the body processes it, and what dose might work best…
Phase 1 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Sep 21, 2026 22:00 UTC
-
Can a Dual-Antibody combo hold ovarian cancer at bay longer?
Disease control Not yet recruitingThis trial is testing whether adding trastuzumab to the standard maintenance drug bevacizumab can delay cancer progression in people with advanced ovarian, fallopian tube, or primary peritoneal cancer. Participants who have completed initial chemotherapy plus bevacizumab without …
Phase 3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Lung cancer combo therapy aims to clear tumors before surgery
Disease control Not yet recruitingThis phase II trial investigates whether combining the immunotherapy adebelizumab with other anti-tumor drugs, given before and after surgery, can improve outcomes for people with resectable non-small cell lung cancer. The study enrolls adults aged 18-70 with stage II or IIIA dis…
Phase 2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Triple-Drug cocktail plus targeted procedure aims to tame incurable liver cancer
Disease control Not yet recruitingThis phase 3 trial tests whether adding three drugs—SHR-8068, adebrelimab, and bevacizumab—to a standard liver-directed procedure (TACE) can better control incurable hepatocellular carcinoma. About 690 adults with liver cancer that cannot be surgically removed will receive either…
Phase 3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Triple-Drug attack aims to stop liver cancer recurrence after surgery
Disease control Not yet recruitingThis phase II trial investigates whether adding SHR-8068 to a two-drug regimen (adebrelimab and apatinib) can improve outcomes for people with liver cancer that can be surgically removed but has a moderate-to-high risk of coming back. Participants receive the drug combination bef…
Phase 2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC